Cargando…

Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors

OBJECTIVE: ABI-007 is a novel Cremophor(®) EL-free nanoparticle albumin-bound paclitaxel. This Phase I study was designed to evaluate tolerability and determine recommended dose for Japanese patients when ABI-007 was administered in every-3-week schedule. Pharmacokinetics of paclitaxel was also asse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamada, Kazuhiko, Yamamoto, Noboru, Yamada, Yasuhide, Mukohara, Toru, Minami, Hironobu, Tamura, Tomohide
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2010
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862657/ https://www.ncbi.nlm.nih.gov/pubmed/20133335 http://dx.doi.org/10.1093/jjco/hyp192

Ejemplares similares

Albumin-bound formulation of paclitaxel (Abraxane(®) ABI-007) in the treatment of breast cancer
por: Miele, Evelina, et al.
Publicado: (2009)

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors
por: Murakami, Haruyasu, et al.
Publicado: (2010)

Safety of nanoparticle albumin-bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports
por: KIMURA, KOSEI, et al.
Publicado: (2013)

Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors
por: Yamamoto, Noboru, et al.
Publicado: (2009)

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas
por: Tian, Zhichao, et al.
Publicado: (2022)

A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors
por: Nokihara, Hiroshi, et al.
Publicado: (2012)

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
por: Hassan, Md Sazzad, et al.
Publicado: (2018)

Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study
por: Oi, Hajime, et al.
Publicado: (2022)

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
por: Wakui, Hiroshi, et al.
Publicado: (2014)

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
por: Chen, Nianhang, et al.
Publicado: (2015)

Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer
por: Di Costanzo, Francesco, et al.
Publicado: (2009)

Albumin-bound paclitaxel in solid tumors: clinical development and future directions
por: Kundranda, Madappa N, et al.
Publicado: (2015)

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Gelatin Methacryloyl Hydrogels Control the Localized Delivery of Albumin-Bound Paclitaxel
por: Vigata, Margaux, et al.
Publicado: (2020)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas
por: Gould, Andrew, et al.
Publicado: (2021)

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors
por: Ueda, Yutaka, et al.
Publicado: (2010)

Repetitive responses to nanoparticle albumin‐bound paclitaxel and carboplatin in malignant pleural mesothelioma
por: Kanai, Osamu, et al.
Publicado: (2016)

Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer
por: Zhang, Changhua, et al.
Publicado: (2013)

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
por: Li, Qingmei, et al.
Publicado: (2018)

Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
por: Giordano, Guido, et al.
Publicado: (2017)

Albumin-bound paclitaxel as new treatment for metastatic cholangiocarcinoma: A case report
por: Martin Huertas, Roberto, et al.
Publicado: (2020)

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
por: Xing, Puyuan, et al.
Publicado: (2017)

Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer
por: Yoshimura, N, et al.
Publicado: (2004)

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
por: Cucinotto, Iole, et al.
Publicado: (2013)

nab-Paclitaxel (Abraxane(®)): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors
por: Iglesias, J
Publicado: (2009)

A Retrospective Study of Efficacy and Safety of Albumin-Bound Paclitaxel in Metastatic Breast Cancer
por: Singh, Rajesh Kumar, et al.
Publicado: (2014)

Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells
por: Vallo, Stefan, et al.
Publicado: (2017)

Ultra-widefield angiographic imaging of albumin-bound paclitaxel-induced cystoid macular edema
por: Lee, Junhyuck, et al.
Publicado: (2019)

MRI-guided microwave ablation and albumin-bound paclitaxel for lung tumors: Initial experience
por: Shen, Xiaokang, et al.
Publicado: (2022)

Pharmacokinetic study of the oral fluorouracil antitumor agent S‐1 in patients with impaired renal function
por: Goto, Keiko, et al.
Publicado: (2019)

Nanoparticle albumin-bound paclitaxel versus solvent-based paclitaxel in breast cancer: A protocol for systemic review and meta-analysis
por: Li, Bingxue, et al.
Publicado: (2021)

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2016)

Macrophage Polarization Contributes to the Anti-Tumoral Efficacy of Mesoporous Nanovectors Loaded with Albumin-Bound Paclitaxel
por: Leonard, Fransisca, et al.
Publicado: (2017)

Tetrahydrocurcumin Chemosensitizes Breast Cancer to Albumin-Bound Paclitaxel by Enhancing SPARC Expression through Demethylation
por: Qiu, Dongjie, et al.
Publicado: (2022)

S-1 and oxaliplatin combined with nanoparticle albumin-bound paclitaxel adjuvant chemotherapy for advanced gastric adenocarcinoma
por: Xia, Yu, et al.
Publicado: (2022)

Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
por: Wang, Hai-ying, et al.
Publicado: (2016)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Nanoparticle Albumin-Bound-Paclitaxel in the Treatment of Metastatic Urethral Adenocarcinoma: The Significance of Molecular Profiling and Targeted Therapy
por: Abaza, Yasmin M., et al.
Publicado: (2014)

Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer
por: Srinivasan, K. N, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rh27c32kvivpornc1f7qnjh635